Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

TEXAS HOSPITAL ASSOCIATION

Filed by CAMERON KRIER MASSEY, INC. DBA SCOUT GR.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
c14af21f-d117-4f6a-a2b5-0f6af330bbce
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

H.R. 1 - One Big Beautiful Bill Act. Expressed opposition to the following items being considered for a budget reconciliation package: capped Medicaid funding, restrictions on provider taxes, restrictions on state directed payment programs, site-neutral payment policies. Expressed support for delaying cuts to Medicaid Disproportionate Share hospitals, extending telehealth flexibilities, extending Medicare-related programs that support rural hospitals, and repealing the nursing home minimum staffing rule. Express support for Centers for Medicare and Medicaid Services (CMS) proposal to collect information from Medicare Advantage organizations (MAO) participating in the Medicare Advantage (MA) program; more specifically, the addition and clarification of data elements that will ensure CMS has appropriate insight into areas where patients and providers are struggling.

Literal federal measure citations: H.R. 1

HCR · Health Issues

Express support for extending enhanced premium tax credits set to expire end of year 2025. Express support for the No Surprises Enforcement Act (legislation to address surprise billing of patients for healthcare services). Responding to request for public comment by the Department of Justice to inform the Anticompetitive Regulations Task Force - provisions related to billing, privacy and security, quality and patient safety, telehealth, and workforce. Request for Department of Health and Human Services to deny drug companies requests to approve unlawful rebate models. Comments to Department of Commerce in response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients (XRIN 0694-XC120); expressing support for increasing domestic supply of pharmaceuticals and expressing concern about tariffs. Response to Office of Management and Budgets (OMB) request for information (RFI) on Deregulation (FR Doc. 2025-06316); comments specifically on billing, payment, and administrative burdens, privacy and security, quality and patient safety, telehealth, and workforce.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.